Pfizer Inc. CEO Aggressively Seeking Deals, Leaves Investors Guessing On AstraZeneca PLC Intentions
(Reuters) - Pfizer Inc (PFE.N), which in May abandoned its $118 billion bid for AstraZeneca Plc (AZN.L), on Tuesday left investors guessing whether it would renew its pursuit of its British rival, but said it was considering other deals.
The largest U.S. drugmaker reported higher-than-expected second-quarter revenue, helped by growing demand for its cancer medicines. But overall sales fell on competition with newer rival drugs and cheaper generics, trends that have quickened Pfizer’s efforts to buy companies and drugs that can fortify its medicine chest.
Help employers find you! Check out all the jobs and post your resume.